← 返回前沿论文

IL-21 通过增强效应 CD8+ T 细胞线粒体 Ca2+介导的运动能力,提升 T 细胞疗法对实体瘤的疗效

英文原题:IL-21 boosts T cell-therapy efficacy for solid tumors by enhancing mitochondrial Ca2+-mediated motility of effector CD8+ T cells.

PubMed 2026/09/21(内容时间) Cancer Immunol Res Q1 · IF 7.9(JCR 2025)

研究概要

细胞运动以随机游走和探索性搜索运动为特征,使效应 CD8+ T 细胞能够在肿瘤内寻找稀少的抗原特异性癌症靶点。

中文摘要

细胞运动性以随机游走和探索性搜索运动为特征,使效应 CD8+ T 细胞能够在肿瘤内寻找稀少的抗原特异性癌症靶点。这对于采用过继性 T 细胞受体(TCR)T 细胞疗法治疗实体癌尤为重要,因为输入的效应 CD8+ T 细胞识别特定的 MHC-I 呈递抗原。细胞运动需要细胞骨架重塑以促进形状变化和移动。在此,我们表明,线粒体 Ca2+ 水平升高对于降低效应 CD8+ T 细胞的细胞骨架硬度至关重要,从而导致获得极化形态和高运动性。IL-21,而非 IL-7 或 IL-15,能够提高效应 CD8+ T 细胞中的线粒体 Ca2+ 水平并增加其运动性,而不影响存活和增殖。IL-21 触发的线粒体 Ca2+ 水平升高是通过线粒体 STAT3 维持线粒体膜电位所驱动的,独立于其转录活性。效应 CD8+ T 细胞运动性的增强导致体外对抗原特异性黑色素瘤细胞的杀伤效力更优。此外,过继性 TCR 特异性效应 CD8+ T 细胞中线粒体 Ca2+ 介导的运动性增强,使该治疗在体内对实体瘤具有更优的抗肿瘤疗效。因此,增强效应 CD8+ T 细胞运动性是提高过继性 T 细胞疗法对实体瘤疗效的一种有前景的策略。

展开英文摘要原文

Cell motility, characterized by random walk and exploratory search movement, enables effector CD8+ T cells to search for sparse antigen-specific cancer targets within a tumor. This is of special relevance for treatment of solid cancers with adoptive T-cell receptor (TCR) T-cell therapy, where administered effector CD8+ T cells recognize specific MHC-I-presented antigens. Cell motility requires cytoskeleton remodeling to facilitate shape changes and movement. Herein, we show that increased mitochondrial Ca2+ levels are essential to reduce cytoskeleton stiffness of effector CD8+ T cells, leading to acquisition of a polarized shape and high motility. IL-21, but not IL-7 or IL-15, was able to raise mitochondrial Ca2+ levels in effector CD8+ T cells and increase their motility without affecting survival and proliferation. This increase in mitochondrial Ca2+ levels triggered by IL-21 was driven by sustaining mitochondrial membrane potential through mitochondrial STAT3, independently of its transcriptional activity. Enhanced motility of effector CD8+ T cells led to a superior killing efficacy of antigen-specific melanoma cells in vitro. Furthermore, enhanced mitochondrial Ca2+-mediated motility of adoptive TCR-specific effector CD8+ T cells resulted in a superior antitumor efficacy of this treatment against solid tumors in vivo. Thus, enhancing effector CD8+ T-cell motility is a promising strategy to boost efficacy of adoptive T-cell therapies against solid tumors.

论文信息

作者
Hoen Rauhut M、Abdullahi F、Walters J、Patel HN、Stich D、Marié IJ、Wen H、Levy DE
单位
University of Colorado Anschutz Medical Campus Aurora, CO United States.United States
期刊
Cancer immunology research2026 Sep 21
原文标识
PubMed 42765849 · DOI 10.1158/2326-6066.CIR-26-0401